Reding Pharmaceutical PD-1 has been approved to conduct clinical trials of squamous cell carcinoma

On September 5, Reding Pharmaceuticals/Incyte INCMGA00012 injection was approved for clinical trials in China for non-surgical, local recurrence or metastatic tube squamous cell carcinoma that has not previously underwent systemic chemotherapy.
INCMGA0012 is a PD-1 monoantiba, has been approved for 4 clinical trials, adaptive diseases for stomach cancer (GC) or gastroesophageal conjunctivism (GEJ) cancer, microsatellite high instability (MSI-H) or DNA misalquatch repair defects (dMMR) endometrial cancer patients, non-small cell lung cancer (NSCLC) and anal squamous cell carcinoma.
, clinical trials for first-line treatment of NSCLC have entered the phase III clinical phase.
squamous cell carcinoma (SCCA) is a rare tumor that accounts for only 2% of the malignant tumors in the digestive tract.
estimates that there are about 27,000 new SCCA cases worldwide each year.
most local early SCCA patients can be cured with chemotherapy, 25% of patients will progress to disease metastasis.